首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷分子呈像/呈影劑

市場調查報告書

商品編碼

1800247

全球顯影劑市場 - 2025 年至 2030 年預測

Global Contrast Agent Market - Forecasts fom 2025 to 2030

出版日期: 2025年08月12日 | 出版商:

Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

顯影劑市場預計將從 2025 年的 70.38 億美元成長到 2030 年的 99.07 億美元，複合年成長率為 7.08%。

由於慢性病盛行率上升以及對超音波、X 光、MRI 和 CT 等診斷影像的需求不斷成長，顯影劑市場預計將在 2025 年至 2030 年間大幅成長。顯影劑在醫療圖像影像中起著重要作用，可提高影像清晰度並支援準確的診斷和治療，尤其是在影像引導程式 (IGS) 中。市場受到成像技術的進步、醫療保健投資的增加以及創新顯影劑研發舉措的增加的推動。北美佔有很大佔有率，而亞太地區預計將因其不斷擴大的醫療保健基礎設施而快速成長。挑戰包括顯影劑的高成本和潛在的副作用。

市場促進因素

慢性病增多

癌症、心血管疾病和糖尿病等慢性疾病的日益普及是顯影劑市場的主要驅動力。美國癌症協會報告稱，2023年美國男性新增癌症病例1,013,310例，美國新增癌症病例948,000例，凸顯了對先進診斷工具日益成長的需求。這些治療需要精確的影像來進行診斷和製定治療計劃，從而推動了對CT和MRI掃描等顯影劑的需求。合併症的高發生率也要求增強影像學檢查能力，這進一步推動了市場成長。

診斷影像需求不斷成長

隨著公眾意識的提升以及CT和MRI等影像設備的普及，診斷影像需求激增，這推動了顯影劑市場的發展。影像導引手術因其即時視覺化、改善手術效果和診斷準確性而日益普及。顯影劑技術創新正在提升影像品質和病患安全性，從而支持市場擴張。微創手術的興起進一步增加了對用於精準診斷的顯影劑的需求。

加大研發力度

研發投入的不斷增加為顯影劑劑的新型應用創造了機會。企業、研究機構和學術機構之間的合作正在推動更安全、更有效、副作用更少的顯影劑的開發。這些努力旨在擴大顯影劑在先進MRI和光譜CT成像等新應用中的使用，滿足尚未滿足的臨床需求，並改善患者預後，從而推動市場成長。

市場限制

顯影劑市場面臨先進影像處理和顯影劑高昂成本的挑戰。某些顯影劑可能有副作用，例如過敏反應和腎毒性，這引發了安全隱患，需要嚴格的測試並遵守相關法規。此外，供應鏈限制和監管複雜性可能會阻礙市場的擴充性。透過經濟高效的創新和更安全的配方來應對這些挑戰，對於實現永續成長至關重要。

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 英國
- 德國
- 法國
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 以色列
- 其他
亞太地區
- 日本
- 中國
- 印度
- 韓國
- 印尼
- 泰國
- 其他

第10章競爭格局及分析

主要企業和策略分析
市場佔有率分析
合併、收購、協議和合作
競爭對手儀表板

第11章：公司簡介

Guerbet Group
Bayer AG
Lantheus Medical Imaging, Inc.
Bracco Diagnostic, Inc.
GE
Curadel, LLC
Daiichi Sankyo Company, Limited
Magnus Health
Spago Nanomedical AB
JB Chemicals & Pharmaceuticals Ltd

第12章調查方法

簡介目錄

Product Code: KSI061612094

The global contrast agent market is expected to grow from USD 7.038 billion in 2025 to USD 9.907 billion in 2030, at a CAGR of 7.08%.

The global contrast agent market is poised for significant growth from 2025 to 2030, driven by the rising prevalence of chronic diseases and increasing demand for diagnostic imaging procedures such as ultrasonography, X-rays, MRI, and CT scans. Contrast agents, critical for enhancing image clarity in medical imaging, support accurate diagnosis and treatment, particularly in image-guided procedures (IGS). The market is propelled by advancements in imaging technology, growing healthcare investments, and rising R&D initiatives for innovative contrast agents. North America holds a significant market share, while Asia-Pacific is expected to grow rapidly due to expanding healthcare infrastructure. Challenges include high costs and potential adverse effects of contrast agents.

Market Drivers

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic conditions, such as cancer, cardiovascular diseases, and diabetes, is a primary driver of the contrast agent market. In 2023, the American Cancer Society reported 1,010,310 new cancer cases in males and 948,000 in females in the United States, highlighting the growing need for advanced diagnostic tools. Conditions like these require precise imaging for diagnosis and treatment planning, boosting demand for contrast agents in procedures like CT and MRI scans. The high prevalence of comorbidities necessitates enhanced imaging capabilities, further driving market growth.

Growing Demand for Diagnostic Imaging

The surge in demand for diagnostic imaging, driven by public awareness and improved accessibility to modalities like CT and MRI, is fueling the contrast agent market. Image-guided procedures are gaining popularity due to their ability to provide real-time visualization, improving surgical outcomes and diagnostic accuracy. Innovations in contrast media, such as iso-osmolar agents, enhance imaging quality and patient safety, supporting market expansion. The growing adoption of minimally invasive procedures further amplifies the need for contrast agents to ensure precise diagnostics.

Rising R&D Initiatives

Increased investment in research and development is creating opportunities for novel contrast agent applications. Collaborative efforts between companies, research institutions, and academic bodies are focused on developing safer, more effective agents with fewer side effects. These initiatives aim to expand the use of contrast agents in emerging applications, such as advanced MRI and spectral CT imaging, driving market growth by addressing unmet clinical needs and improving patient outcomes.

Market Restraints

The contrast agent market faces challenges due to the high cost of advanced imaging procedures and contrast media, which can limit accessibility in cost-sensitive regions. Potential adverse effects, such as allergic reactions or nephrotoxicity associated with certain contrast agents, pose safety concerns, necessitating rigorous testing and regulatory compliance. Additionally, supply chain constraints and regulatory complexities may hinder market scalability. Addressing these challenges through cost-effective innovations and safer formulations will be critical for sustained growth.

Market Segmentation

By Type

The market is segmented into iodinated, gadolinium-based, barium-based, and microbubble contrast agents. Iodinated agents dominate due to their widespread use in CT imaging, while gadolinium-based agents are critical for MRI scans. Microbubble agents are gaining traction in ultrasound imaging for their ability to enhance vascular visualization.

By Application

The market includes diagnostic imaging (CT, MRI, ultrasound) and image-guided procedures. Diagnostic imaging holds the largest share, driven by the rising need for accurate diagnosis in chronic disease management. Image-guided procedures are a fast-growing segment due to their increasing use in minimally invasive surgeries.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America leads, driven by a robust healthcare sector, high cancer prevalence, and product innovations like Fresenius Kabi's FDA-approved generic iodixanol contrast agent launched in 2023. Asia-Pacific is expected to grow rapidly, fueled by expanding healthcare infrastructure and rising chronic disease rates in countries like China and India.

The contrast agent market is set for robust growth from 2025 to 2030, driven by the rising prevalence of chronic diseases, increasing demand for diagnostic imaging, and R&D advancements. Despite challenges like high costs and safety concerns, the market's outlook is positive, particularly in North America and Asia-Pacific. Industry players must focus on developing safer, cost-effective agents and leveraging collaborations to meet the growing demand for advanced imaging solutions.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2020 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Type

Iodinated
Barium-based
Microbubble
Gadolinium-based

By Modality

X-ray/CT
MRI
Ultrasound

By Route of Administration

Intravascular
Oral
Rectal
Others

By Indication

Oncology
Cardiovascular Disease
Neurological Disorders
Gastrointestinal Disorders
Nephrological Disorders
Musculoskeletal Disorders
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Japan
South Korea
Taiwan
Thailand
Indonesia
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL CONTRAST AGENT MARKET BY TYPE

5.1. Introduction
5.2. Iodinated
5.3. Barium-based
5.4. Microbubble
5.5. Gadolinium-based

6. GLOBAL CONTRAST AGENT MARKET BY MODALITY

6.1. Introduction
6.2. X-ray/CT
6.3. MRI
6.4. Ultrasound

7. GLOBAL CONTRAST AGENT MARKET BY ROUTE OF ADMINISTRATION

7.1. Introduction
7.2. Intravascular
7.3. Oral
7.4. Rectal
7.5. Others

8. GLOBAL CONTRAST AGENT MARKET BY INDICATION

8.1. Introduction
8.2. Oncology
8.3. Cardiovascular Disease
8.4. Neurological Disorders
8.5. Gastrointestinal Disorders
8.6. Nephrological Disorders
8.7. Musculoskeletal Disorders
8.8. Others

9. GLOBAL CONTRAST AGENT MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
9.5. Middle East & Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
9.6. Asia Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others